Ted Okon Talks About the Issues With Reimbursement

Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.

The FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.

Frailty is common among older adults with blood cancers and strongly predicts survival, independent of age.

The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.

Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.